Sheng J. Zhang

270 Dong An Road
Shanghai, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Antibody-Drug Conjugates Targeting Resistance-Associated Signaling Pathways: Recent Advances and Future Perspectives.

Antibody-Drug Conjugates Targeting Resistance-Associated Signaling Pathways: Recent Advances and Future Perspectives.

Journal: International journal of molecular sciences

Published: March 23, 2026

Sequential HER2-targeted antibody-drug conjugate therapy for acquired resistance in a 55-year-old male kidney transplant recipient with metastatic urothelial carcinoma: a case report.

Sequential HER2-targeted antibody-drug conjugate therapy for acquired resistance in a 55-year-old male kidney transplant recipient with metastatic urothelial carcinoma: a case report.

Journal: Translational cancer research

Published: March 15, 2026

Efficacy and safety of camrelizumab plus apatinib in advanced urachal cancer (RUN-SC-0102): a single-arm, multicentre, phase 2 trial in China.

Efficacy and safety of camrelizumab plus apatinib in advanced urachal cancer (RUN-SC-0102): a single-arm, multicentre, phase 2 trial in China.

Journal: EClinicalMedicine

Published: December 30, 2025

Sequential therapy of metastatic urothelial cancer with monomethyl auristatin E (MMAE)-containing antibody-drug conjugates for different targets.

Sequential therapy of metastatic urothelial cancer with monomethyl auristatin E (MMAE)-containing antibody-drug conjugates for different targets.

Journal: Tumori

Published: September 29, 2025

Clinical characteristics of the ALK fusion-positive bladder PMP and efficacy of lorlatinib: a two-case report and literature review.

Clinical characteristics of the ALK fusion-positive bladder PMP and efficacy of lorlatinib: a two-case report and literature review.

Journal: The oncologist

Published: June 08, 2025

Case report: Abscopal response and reversal of PD-1 resistance in a patient with nephroblastoma following radiofrequency ablation.

Case report: Abscopal response and reversal of PD-1 resistance in a patient with nephroblastoma following radiofrequency ablation.

Journal: Frontiers in oncology

Published: June 03, 2025

Carelizumab and rivoceranib for advanced extramammary Paget's disease: an investigator-initiated multicenter, single-arm, phase II trial.

Carelizumab and rivoceranib for advanced extramammary Paget's disease: an investigator-initiated multicenter, single-arm, phase II trial.

Journal: The oncologist

Published: May 10, 2025

High-efficient refolding and purification of recombinant human interleukin-2 from inclusion bodies.

High-efficient refolding and purification of recombinant human interleukin-2 from inclusion bodies.

Journal: Protein expression and purification

Published: April 10, 2025

Apatinib monotherapy for pretreated advanced squamous cell carcinoma of the penis: a phase II trial.

Apatinib monotherapy for pretreated advanced squamous cell carcinoma of the penis: a phase II trial.

Journal: The oncologist

Published: March 21, 2025

Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget's disease.

Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget's disease.

Journal: The oncologist

Published: August 09, 2024

Does Duration of Adverse Events Matter in Cancer Clinical Trials?

Does Duration of Adverse Events Matter in Cancer Clinical Trials?

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 24, 2024

Sunitinib for the treatment of phaeochromocytomas and paragangliomas.

Sunitinib for the treatment of phaeochromocytomas and paragangliomas.

Journal: Lancet (London, England)

Published: March 29, 2024

Showing 1-12 of 60

Last Updated: 09/26/2026